CareCloud (CCLD) Q4 2025 earnings review
Transformation Validated: First Positive Annual EPS Since IPO Alongside Inpatient Expansion
CareCloud capped off a transformative 2025 with $34.4M in Q4 revenue (accelerating 22% YoY) and achieved its first full-year positive GAAP EPS ($0.10) since its 2014 IPO. While GAAP Net Income dipped 12% YoY in Q4 due to expected acquisition-related amortization and integration costs, adjusted earnings metrics showcased strong double-digit growth. The company successfully executed four acquisitions in 2025—most notably Medsphere—to pivot into the inpatient hospital market, fully funding these moves with internally generated cash flow. Management enters 2026 with strong momentum, guiding for continued revenue growth and a doubling of GAAP EPS.
🐂 Bull Case
CareCloud completed four acquisitions in 2025, fundamentally transforming its Total Addressable Market (TAM), and fully repaid the $9.3M drawn on its line of credit by year-end using internally generated cash flow.
The newly launched stratusAI Desk Agent is already automating approximately 75% of inbound calls. Management notes that AI and acquisitions are now 'one unified growth engine,' driving cross-sell opportunities and internal margin expansion.
🐻 Bear Case
Absorbing four distinct companies (including Medsphere and Map App) within a single year introduces significant technological and cultural integration hurdles.
Despite a 22% jump in Q4 revenue, GAAP Operating Income fell 10% YoY. Increased amortization of intangible assets will likely act as a structural headwind to GAAP profitability in the near term.
⚖️ Verdict: 🟢
Bullish. CareCloud proved it can execute its M&A strategy without relying on dilutive equity or suffocating debt. By hitting its first positive annual EPS milestone and aggressively capturing the inpatient market, the company has successfully transitioned from a turnaround story to a sustainable growth engine.
Key Themes
Strategic Pivot to Inpatient Market Validated
The August 2025 acquisition of Medsphere drastically shifted CareCloud from a purely ambulatory provider to a full-continuum platform. The Q4 revenue acceleration to $34.4M (+22% YoY) reflects the immediate top-line impact of this expanded portfolio, which now includes inpatient EHR, RCM, analytics, and EDIS (Emergency Department Information Systems).
stratusAI Adoption Leading Efficiency Gains
The 'AI Center of Excellence' has successfully launched the stratusAI Desk Agent and Voice Audit. The Desk Agent is currently automating approximately 75% of inbound calls. This acts as a dual driver: it creates a compelling upsell product for clients and significantly reduces CareCloud's own internal back-office service costs.
Aggressive, Self-Sustaining Capital Allocation
The company's cash generation is operating at peak efficiency. Operating cash flow grew 38% YoY to $28.6M. With this capital, CareCloud fully funded four acquisitions, completely paid off $9.3M drawn on its line of credit by year-end, and paid 13 consecutive monthly preferred dividends. This non-dilutive approach to growth is a major structural advantage.
GAAP Profitability Masked by Amortization
While Non-GAAP Adjusted Operating Income grew 14.8% YoY in Q4, GAAP Operating Income actually decelerated, falling 9.8% to $3.1M. Management attributed this to the amortization of acquired intangibles and integration costs from the Medsphere deal. Investors must monitor how long these integration expenses will depress reported bottom-line results.
Organic Growth Transparency
Given the four acquisitions closed in 2025, the 21.9% Q4 revenue growth is heavily skewed by inorganic additions. The company did not clearly break out what portion of the $34.4M in Q4 revenue was generated from the legacy CareCloud client base versus the newly acquired Medsphere and Map App accounts.
Other KPIs
Accelerating. Grew 38.4% YoY from $20.6M in 2024. This metric is the absolute cornerstone of CareCloud's current strategy, providing the fuel for acquisitions, debt reduction, and dividend payments without the need to raise outside capital.
Stable and accelerating. Up 14.5% YoY from $24.1M. Despite integration hurdles and massive AI investments, the company successfully hit the upper half of its previous FY25 guidance ($26 - $28 million).
Guidance
Stable. The $130M midpoint implies a 7.9% YoY growth rate over FY25's $120.5M. This indicates that management expects healthy cross-selling and full-year contribution from 2025 acquisitions, though it reflects a normalization from the 22% growth spike seen in Q4.
Accelerating. Management expects EPS to more than double from the $0.10 achieved in FY25 (a 100-130% increase). This signals confidence that upfront integration costs and deal-related expenses will wane, allowing top-line growth to flow directly to common shareholders.
Accelerating slightly. The $30M midpoint implies a 9% YoY increase from 2025's $27.5M, keeping margins relatively stable as the company scales its expanded inpatient offerings.
Key Questions
Organic vs. Inorganic Growth
Of the 22% revenue growth witnessed in Q4, and the 8% growth guided for 2026, what percentage is driven strictly by organic expansion versus the inorganic contribution of Medsphere and Map App?
Amortization Headwinds Timeline
GAAP Net Income declined 12% in Q4 due to integration and amortization costs. When do you expect these specific acquisition-related accounting headwinds to normalize?
Inpatient Market Penetration
Following the acquisition of Medsphere, how are initial cross-selling efforts of CareCloud's RCM and AI tools to the newly acquired hospital client base tracking?